ImmunityBio converts from Immunomedics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics

IBRX 2.065

-2.1%

9:49 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jargonweary	5/6/2025 10:37:57 AM
	4 Recommendations Recommended By dorightbythem erippetoe Fitzhughlaw TripleE3 Read Replies (1) of 1229

I am prepared to believe that the FDA encouraged them to file and, if true, that would reflect an optimistic view by the FDA. However, having encouraged IBRX to file does not mean that the FDA is therefore bound to accept a filing that is either incomplete, incorrect, inadequate or otherwise insufficient for FDA review. It seems likely to me that the company was so enthused by the initial FDA meetings that they assumed the filing was a slam dunk and then put together a sloppy, inadequate filing taking for granted that it would be accepted. Again, this is unforgivable and indicates this management team simply can’t hit big league pitching. Whatever one thinks about PSS, he is either naive or delusional if he just lets this go. Either management egregiously misread the FDA’s intentions or they filed a poorly prepared, inadequate filing…or both. In my mind no explanation exonerates Adcock. Investors — and potential investors — need to see that the root cause of this screw up is corrected.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next